trial

Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States

NCTId NCT02569307
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 326 (actual)
Sponsored by Pakistan Institute of Living and Learning
Primary completion 2018-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
326 (actual)
Study type
Interventional
Allocation
Randomized
Model
Factorial
Masking
Triple
Start
2015-10
Primary completion
2018-12
Eligibility
ALL · 16 Years · 35 Years

Interventions & indications

Drugs
MinocyclineOmega-3 fatty acids

Sponsors

Pakistan Institute of Living and LearningLead Sponsor

Investigators

1
Dr.Inti Qurashi, MDPrincipal Investigator

Sites

7 total
Karachi, PakistanKarachi, PakistanKarachi, PakistanKarachi, PakistanKarachi, PakistanKarachi, PakistanKarachi, Pakistan

Linked catalysts

1
Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk M — primary completion2018-12

Facts & assertions

4 sourced
Enrollment
326
Phase
PHASE2
Primary Completion Date
2018-12
Status
COMPLETED
relationships
The graph out of here
drug
Minocycline
drug
Omega-3 fatty acids
drug
lead_sponsor
Pakistan Institute of Living and Learning
company
indication
At Risk Mental State (ARMS)
indication
Psychosis
indication
Psychotic Disorders
indication
investigator
Dr.Inti Qurashi, MD
person